A phase I/II study of bortezomib and capecitabine in patients with metastatic breast cancer previously treated with taxanes and/or anthracyclines

Annals of Oncology

Volumn 19, Issue 5, 2008, Pages 871-876

  Schmid, P ^a   Kuhnhardt D ^b   Kiewe, P ^b   Lehenbauer Dehm, S ^b   Schippinger, W ^c   Greil, R ^d   Lange, W ^e   Preiss, J ^c   Niederle, N ^f   Brossart, P ^g   Freier, W ^h   Kummel S ⁱ   Van de Velde, H ^j   Regierer, A ^b   Possinger, K ^b  

^a CHARING CROSS HOSPITAL   (United Kingdom)

^b CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^c Charite Campus Benjamin Franklin ^*  (Germany)

^d Laboratory of Immunological and Molecular Cancer Research   (Austria)

^e Johanniter Krankenhaus   (Germany)

^f KLINIKUM LEVERKUSEN   (Germany)

^g UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

^h Practice for Oncology and Haematology   (Germany)

ⁱ UNIVERSITY OF DUISBURG ESSEN   (Germany)

^j JANSSEN RESEARCH AND DEVELOPMENT   (Belgium)

more..

Author keywords

Bortezomib; Capecitabine; Chemotherapy; Metastatic breast cancer; Phase I study; Proteasome inhibition

Indexed keywords

ALKYLATING AGENT; ANTHRACYCLINE DERIVATIVE; BORTEZOMIB; CAPECITABINE; FLUOROURACIL; GEMCITABINE; NAVELBINE; SEROTONIN 3 ANTAGONIST; TAXANE DERIVATIVE; TRASTUZUMAB; VINCA ALKALOID;

ADULT; AGED; ANEMIA; ARTICLE; BONE METASTASIS; BREAST CANCER; CHEMOTHERAPY INDUCED EMESIS; CLINICAL ARTICLE; CLINICAL TRIAL; CONSTIPATION; DIARRHEA; DRUG DOSE ESCALATION; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG ERUPTION; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; GASTROINTESTINAL DISEASE; HAND FOOT SYNDROME; HEMATOLOGIC DISEASE; HUMAN; HYPERBILIRUBINEMIA; INFECTION; LEUKOPENIA; LIVER METASTASIS; LUNG METASTASIS; MAXIMUM TOLERATED DOSE; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; OVERALL SURVIVAL; PERIPHERAL NEUROPATHY; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; SENSORY NEUROPATHY; SOFT TISSUE METASTASIS; STOMATITIS; THROMBOCYTOPENIA; VISCERAL METASTASIS;

ANTHRACYCLINES; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BORONIC ACIDS; BREAST NEOPLASMS; CARCINOMA; DEOXYCYTIDINE; DISEASE PROGRESSION; DRUG RESISTANCE, NEOPLASM; FEMALE; FLUOROURACIL; HEMATOLOGIC DISEASES; HUMANS; MAXIMUM TOLERATED DOSE; PERIPHERAL NERVOUS SYSTEM DISEASES; PYRAZINES; SALVAGE THERAPY; SURVIVAL ANALYSIS; TAXOIDS; TREATMENT OUTCOME;

EID: 43049100774     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdm569     Document Type: Article

References (20)

1. Geyer CE, Forster J, Lindquist D et al. Lapatinib plus capecitabine for HER2-positive advanced breast cancer. N Engl J Med 2006; 355(26): 2733-2743.
2. Miller KD, Chap LI, Holmes FA et al. Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer. J Clin Oncol 2005; 23(4): 792-799.
3. Vahdat LT, Thomas E, Li R et al. Phase III trial of ixabepilone plus capecitabine compared to capecitabine alone in patients with metastatic breast cancer (MBC) previously treated or resistant to an anthracycline and resistant to taxanes. J Clin Oncol, 2007 ASCO Annual Meeting Proceedings Part I. 2007; 25 (18 Suppl), 1006.
4. King RW, Deshaies RJ, Peters J-M, Kirschner MW. How proteolysis drives the cell cycle. Science 1996; 274: 1652-1659.
5. Sherr CJ. Cancer cell cycles. Science 1996; 274: 1672-1677.
6. Read MA, Neish AS, Luscinskas FW et al. The proteasome pathway is required for cytokine-induced endothelial-leukocyte adhesion molecule expression. Immunity 1995; 2: 493-506.
7. Palombella VJ, Rando OJ, Goldberg AL, Maniatis T. The ubiquitin-proteasome pathway is required-for processing the NF-κB1 precursor protein and the activation of NF-κB. Cell 1994; 78: 773-785.
8. Teicher BA, Ara G, Herbst R et al. The proteasome inhibitor PS-341 in cancer therapy. Clin Cancer Res 1999; 5(9): 2638-2645.
9. Cusack JC, Liu R, Houston M et al. Enhanced chemosensitivity to CPT-11 with proteasome inhibitor PS-341: Implications for systemic nuclear factor-kappaB inhibition. Cancer Res 2001; 61(9): 3535-3540.
10. Shah SA, Potter MW, McDade TP et al. 26S proteasome inhibition induces apoptosis and limits growth of human pancreatic cancer. J Cell Biochem 2001; 82(1): 110-122.
11. Bold RJ, Virudachalam S, McConkey DJ. Chemosensitization of pancreatic cancer by inhibition of the 26S proteasome. J Surg Res 2001; 100: 11-17.
12. Pink M, Pien CS, Worland P et al. PS-341 enhances chemotherapeutic effect in human xenograft models. Proc Am Assoc Cancer Res 2002; 43: 158.
13. Milano A, laffaioli RV, Caponigro F. The proteasome: A worthwhile target for the treatment of solid tumours? Eur J Cancer 2007; 43(7): 1125-33.
14. Papandreou CN, Dallani DD, Nix,D et al. Phase I trial of the proteasome inhibitor bortezomib in patients with advanced solid tumors with observations in androgen-independent prostate cancer. J Clin Oncol 2004; 22: 2108-2121.
15. Yang CH, Gonzalez-Angulo AM, Reuben JM et al. Bortezomib (VELCADE) in metastatic breast cancer: Pharmacodynamics, biological effects, and prediction of clinical benefits. Ann Oncol 2006; 17(5): 813-817.
16. Lara PN, Chansky K, Davies AM et al. Bortezomib (PS-341) in relapsed or refractory extensive stage small cell lung cancer: A Southwest Oncology Group phase II trial (S0327). J Thorac Oncol 2006; 1(9): 996-1001.
17. Mortenson MM, Schlieman MG, Virudachalam S, Bold RJ. Effects of the proteasome inhibitor bortezomib alone and in combination with chemotherapy in the A549 non-small-cell lung cancer cell line. Cancer Chemother Pharmacol 2004; 54(4): 343-353.
18. Fahy BN, Schlieman MG, Virudachalam S, Bold RJ. Schedule-dependent molecular effects of the proteasome inhibitor bortezomib and gemcitabine in pancreatic cancer. J Surg Res 2003; 113(1): 88-95.
19. Caraglia M, Marra M, Budillon A et al. Chemotherapy regimen GOLF induces apoptosis in colon cancer cells through multi-chaperone complex inactivation and increased Raf-1 ubiquitin-dependent degradation. Cancer Biol Ther 2005; 4(10): 1159-1167.
20. Wan L, Cao D, Zeng J et al. Modulation of uridine phosphorylase gene expression by tumour necrosis factor-alpha enhances the antiproliferative activity of the capecitabine intermediate 5′-deoxy-5-fluorouridine in breast cancer cells. Mol Pharmacol 2006; 69(4): 1389-1395.